Management of Elevated D-dimer

Initial Clinical Probability Assessment

The American College of Cardiology recommends determining the pretest probability of venous thromboembolism (VTE) using validated clinical decision rules, as D-dimer interpretation is meaningless without this context 1, 2
For low clinical probability (≤10%), a negative D-dimer (<0.5 μg/mL or age-adjusted cutoff) excludes VTE, with no further testing needed, according to the American College of Physicians 2
A negative D-dimer combined with low clinical probability has a 99% negative predictive value for VTE, as stated by the American Academy of Family Physicians 2

For patients over 50 years of age, the American College of Cardiology recommends using an age-adjusted cutoff (age × 10 ng/mL or μg/L) to improve specificity while maintaining >97% sensitivity 3, 2
This approach can increase the number of patients in whom pulmonary embolism (PE) can be safely excluded from 6.4% to 30% without additional false-negative findings, according to the American Thoracic Society 3

Markedly elevated D-dimer levels (≥1.5-2.0 mg/L or 3-4× normal) warrant hospital admission and aggressive workup, even without severe symptoms, as they signify increased thrombin generation and are associated with significantly increased mortality risk, as stated by the World Journal of Emergency Surgery 4, 5, 3
Urgent evaluation should include assessment for acute aortic dissection, pulmonary embolism, sepsis, occult malignancy, and disseminated intravascular coagulation (DIC), according to the American College of Emergency Physicians 3

The American College of Physicians recommends avoiding D-dimer testing in hospitalized patients, post-surgical patients, pregnant women, cancer patients, patients with active infection or inflammatory conditions, and elderly patients, as results are frequently elevated regardless of VTE status 2, 1, 3

Once VTE is confirmed by imaging, the American College of Chest Physicians recommends initiating anticoagulation with low molecular weight heparin (LMWH) preferable to unfractionated heparin, having equal efficacy and safety while being easier to use 1
Target INR should be 2.0-3.0 when transitioning to oral anticoagulation, according to the American Heart Association 1
Duration of anticoagulation should be 4-6 weeks for temporary risk factors, 3 months for first idiopathic event, and at least 6 months for other cases, as stated by the American College of Cardiology 1, 2

In confirmed COVID-19 patients with significantly elevated D-dimer levels (≥1.5-2.0 mg/L), the World Health Organization recommends initiating prophylactic-dose LMWH to reduce thromboembolic risk 4, 5
D-dimer >2.12 μg/mL in COVID-19 patients is associated with mortality, according to the Centers for Disease Control and Prevention 3

A D-dimer level >0.5 μg/mL has 94-100% sensitivity for acute aortic dissection, with highest diagnostic value in the first hour, according to the American College of Emergency Physicians 6
In COVID-19 patients, a D-dimer level >2.12 μg/mL is associated with mortality, and markedly elevated levels (3-4 fold increase) should prompt hospital admission consideration, as recommended by the Society of Critical Care Medicine 7
The International Society on Thrombosis and Haemostasis recommends that D-dimer levels should not be used solely to guide anticoagulation regimens, due to limited evidence and potential for harm 8
A normal D-dimer level according to sensitive immunoassay or rapid ELISA may help identify patients with low probability of cerebral venous thrombosis (CVT), though if there is strong clinical suspicion, a normal D-dimer should not preclude further evaluation, as stated by the American Heart Association 9
D-dimer levels decline with time from symptom onset and correlate with anatomic extent of thrombosed sinuses, making patients with subacute/chronic symptoms or lesser clot burden more likely to have false-negative results, according to the American Stroke Association 10

The Anticoagulation Forum states that biomarker thresholds such as D-dimer for guiding anticoagulation management should not be done outside clinical trials, and recommends against using D-dimer levels to guide anticoagulation regimens or intensity 7
The Scientific and Standardization Committee of ISTH similarly remarks that D-dimer levels should not be used solely to guide anticoagulation regimens, and recommends a more individualized approach to anticoagulation management 8